IGF OT IGF NEUROPSYCHOLOGICAL ASSESSMENT SYSTEM FOR CANCER PATIENTS

Decline in cognitive ability is a major quality of life problem for many cancer survivors This problem is affected bywhich treatments a particular individual receives Unfortunately research has provided little guidance on whichtreatment may be best for an individual based on unfavorable cognitive side effects To help researchers fill thisinformation gap and provide doctors and patients with the guidance they need we propose to develop aneuropsychological assessment system that is designed specifically for cancer patients and survivors This system ismobile self administered and has minimal practice effects The neurocognitive content has been proven sensitive tothe subtle cognitive effects of cancer treatment and is appropriate for repeated administration The mobile battery iscross platform and uses instruction videos and speech recognition for self administration and automated scoring Thedata from the battery is automatically uploaded to a secure server for scoring Two web portals one for clinicians theother for researchers offer online ordering of tests review of results and even protocol customization The Creareteam is very well qualified to develop and commercialize this system by leveraging software that Creare and itscollaborators have previously developed and validated for mobile neurocognitive assessment mobile hearingassessment and medication adherence